Latest Advances in Lung Cancer Research

A new NYT report shows that only a small fraction of people who qualify for lung-cancer screening get tested, leaving many early cancers undetected.

A Forbes article warns that few eligible Americans get lung cancer screening the and cancellation of a USPSTF meeting could delay important updates, worsening underuse.

Study of 1,143 lung cancer patients shows improved MET exon 14 mutation detection methods help select better targeted treatments.

Researchers developed RARE-seq, an ultrasensitive blood test detecting cell-free RNA that identifies early-stage lung cancer and monitors treatment resistance.

Chest CT scans used for lung cancer screening can do more than just find early lung cancer. These scans can also detect heart problems and early emphysema, offering a three-in-one health check for people at risk.

A study of over 10,000 people showed that sticking with regular lung cancer screening leads to better detection of early-stage cancer. However, fewer people returned for follow-up screenings each year.

A new JAMA review shows that small cell lung cancer, which affects 95% smokers and has only 12-30% five-year survival, is seeing breakthrough improvements with immunotherapy extending survival to 56 months for early-stage disease, though advanced cases remain challenging with most patients relapsing within three months.

New blood test using ctDNA methylation biomarkers shows promise for early lung cancer detection, potentially improving treatment outcomes for patients.

New study reveals higher lung cancer incidence in women under 65 than in men, with rates increasing among younger women despite declining smoking trends.

The Monarch Platform robotic tool has revolutionized the way lung cancer is diagnosed and treated at Baptist Health. This cutting-edge technology provides a real-time, high-definition view of the airways, enabling doctors to identify and biopsy suspicious lung nodules with increased accuracy.

Mount Sinai study finds liquid biopsies measuring PD-L1 may better predict lung cancer response to immunotherapy than traditional tumor biopsies.